Epigenomics AG | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
7,277.00
8,854.00
8,985.00
11,161.00
10,235.00
12,692
Depreciation, Depletion & Amortization
799.00
770.00
668.00
356.00
343.00
308
Other Funds
4.00
475.00
293.00
166.00
413.00
937
Funds from Operations
6,474.00
7,609.00
8,610.00
11,782.00
9,479.00
11,447
Changes in Working Capital
31.00
388.00
498.00
1,483.00
79.00
1,113
Net Operating Cash Flow
6,505.00
7,221.00
8,112.00
13,265.00
9,558.00
10,334
Capital Expenditures
20.00
874.00
213.00
376.00
220.00
Net Investing Cash Flow
20.00
874.00
144.00
397.00
566.00
Issuance/Reduction of Debt, Net
2,867.00
3,425.00
4,169.00
4,169.00
6,398.00
Net Financing Cash Flow
11,527.00
7,603.00
9,032.00
17,422.00
11,499.00
Net Change in Cash
5,002.00
492.00
1,064.00
3,752.00
1,295.00
Free Cash Flow
6,521.00
8,089.00
8,318.00
13,472.00
9,741.00
Deferred Taxes & Investment Tax Credit
-
-
-
1,143.00
-
-
Other Sources
-
-
357.00
871.00
17.00
Change in Capital Stock
8,660.00
4,178.00
4,863.00
13,253.00
5,101.00
Exchange Rate Effect
-
-
-
8.00
80.00
Other Uses
-
-
-
892.00
363.00

About Epigenomics

View Profile
Address
Geneststraße 5
Berlin Berlin 10829
Germany
Employees -
Website http://www.epigenomics.de
Updated 07/08/2019
Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. It offers Epi proColon, a blood-based test for the early detection of colorectal cancer; Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer, and Epi BiSKit, a kit for the preparation of purified, bisulfite-converted DNA. The comapny was founded by Oliver Schacht, Christian Piepenbrock, Kurt Berlin, Jörn Walter, and Ivo Gut on April 30, 1997 and is headquartered in Berlin, Germany.